The Role of IL-17 Cytokines in Psoriasis

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2021 Dec 2

PMID 34853779

Citations 30

Authors

Megan Mosca

Julie Hong

Edward Hadeler

Marwa Hakimi

Wilson Liao

Tina Bhutani

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory skin condition associated with immune dysregulation. The immunologic cascade mediated by the interleukin (IL)-17 pathway plays a critically important role in the pathogenesis of psoriasis. The IL-17 effectors (IL-17A, IL-17C, IL-17E, and IL17F) act on keratinocytes, endothelial cells, and immune cells to stimulate epidermal hyperplasia and the pro-inflammatory feed-forward cycle seen within plaque psoriasis. The IL-17 pathway is also hypothesized to modulate the inflammatory responses linking comorbid systemic diseases with psoriasis. Furthermore, the robust clinical response seen with current and emerging therapies targeting IL-17 emphasizes the importance of the IL-17 cytokines in the pathogenesis of psoriasis.

Citing Articles

Single-cell RNA sequencing of circulating immune cells supports inhibition of and translation as psoriatic arthritis biomarkers.

Garrido A, Machhar R, Cruz-Correa O, Ganatra D, Crome S, Wither J Front Immunol. 2025; 16:1483393.

PMID: 39991156 PMC: 11842318. DOI: 10.3389/fimmu.2025.1483393.

Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics.

Lazaridou E, Apalla Z, Ravanidis S, Stefanou G, Vellopoulou K, Tsolakidis A Arch Dermatol Res. 2025; 317(1):310.

PMID: 39873811 DOI: 10.1007/s00403-024-03746-y.

Transcriptomic Analysis Identifies Disease Severity and Therapeutic Response in Psoriasis.

Shrotri S, Daamen A, Kingsmore K, Bachali P, Grammer A, Lipsky P JID Innov. 2025; 5(2):100333.

PMID: 39816445 PMC: 11732706. DOI: 10.1016/j.xjidi.2024.100333.

Prevalence of fungal colonization among patients with psoriasis in difficult-to-treat areas: impact of apremilast on mycotic burden and clinical outcomes.

Campione E, Cosio T, Pistoia E, Artosi F, Shumack R, Borselli C Front Immunol. 2024; 15:1508489.

PMID: 39720714 PMC: 11666449. DOI: 10.3389/fimmu.2024.1508489.

Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post-marketing surveillance.

Fujishige A, Seko N J Dermatol. 2024; 52(1):11-23.

PMID: 39611573 PMC: 11700941. DOI: 10.1111/1346-8138.17499.

References

Li Y, Zhu L, Chu Z, Yang T, Sun H, Yang F . Characterization and biological significance of IL-23-induced neutrophil polarization. Cell Mol Immunol. 2017; 15(5):518-530. PMC: 6068162. DOI: 10.1038/cmi.2017.39. View

Bagel J, Nia J, Hashim P, Patekar M, de Vera A, Hugot S . Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatol Ther (Heidelb). 2018; 8(4):571-579. PMC: 6261116. DOI: 10.1007/s13555-018-0265-y. View

Zafiriou E, Daponte A, Siokas V, Tsigalou C, Dardiotis E, Bogdanos D . Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?. Front Immunol. 2021; 12:699848. PMC: 8334867. DOI: 10.3389/fimmu.2021.699848. View

Lebwohl M, Gordon K, Gallo G, Zhang L, Paul C . Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2019; 34(2):301-309. PMC: 7028252. DOI: 10.1111/jdv.15921. View

Armstrong A, Read C . Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. DOI: 10.1001/jama.2020.4006. View

Schuler R, Brand A, Klebow S, Wild J, Veras F, Ullmann E . Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. J Invest Dermatol. 2018; 139(3):638-647. DOI: 10.1016/j.jid.2018.09.021. View

Egeberg A, Gisondi P, Carrascosa J, Warren R, Mrowietz U . The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020; 34(8):1695-1706. PMC: 7496750. DOI: 10.1111/jdv.16273. View

Bissonnette R, Luger T, Thaci D, Toth D, Lacombe A, Xia S . Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018; 32(9):1507-1514. PMC: 6175198. DOI: 10.1111/jdv.14878. View

Madhur M, Lob H, McCann L, Iwakura Y, Blinder Y, Guzik T . Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2009; 55(2):500-7. PMC: 2819301. DOI: 10.1161/HYPERTENSIONAHA.109.145094. View

10.

Puig L, Bakulev A, Kokhan M, Samtsov A, Khairutdinov V, Morozova M . Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021; 11(4):1319-1332. PMC: 8322379. DOI: 10.1007/s13555-021-00554-4. View

11.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

12.

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

13.

Owczarczyk-Saczonek A, Placek W . Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int J Dermatol. 2016; 56(3):260-268. DOI: 10.1111/ijd.13420. View

14.

Davami M, Baharlou R, Vasmehjani A, Ghanizadeh A, Keshtkar M, Dezhkam I . Elevated IL-17 and TGF-β Serum Levels: A Positive Correlation between T-helper 17 Cell-Related Pro-Inflammatory Responses with Major Depressive Disorder. Basic Clin Neurosci. 2016; 7(2):137-42. PMC: 4892318. DOI: 10.15412/J.BCN.03070207. View

15.

Gotesman R, Vender R . Bimekizumab for Moderate-to-Severe Plaque Psoriasis. Skin Therapy Lett. 2021; 26(3):1-4. View

16.

Armstrong A, Harskamp C, Armstrong E . Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013; 68(4):654-662. DOI: 10.1016/j.jaad.2012.08.015. View

17.

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

18.

Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sorensen K . Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015; 46(3):793-9. DOI: 10.1161/STROKEAHA.114.006516. View

19.

Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View

20.

Pirowska M, Obtulowicz A, Lipko-Godlewska S, Gozdzialska A, Podolec K, Wojas-Pelc A . The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatol Alergol. 2018; 35(4):360-366. PMC: 6130144. DOI: 10.5114/ada.2018.77665. View